PP01.14 Paired Sample Analyses of NSCLC After SCLC Transformation
Brinda Gupta(Georgetown University), Stephen V. Liu(Georgetown University), Ari M. Vanderwalde(West Cancer Center), Jennifer A. Marks(Dana-Farber Cancer Institute), Heloisa P. Soares(University of Utah), Misty Dawn Shields(Indiana University Health), Sonam Puri(University of Utah), Jorge J. Nieva(University of Southern California), Balázs Halmos(Montefiore Medical Center), Kieran Sweeney(Caris Life Sciences (United States)), C. Patrick(Penn State Milton S. Hershey Medical Center), Andrew Elliott(Caris Life Sciences (United States))
Cited by 0
Related Papers
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)
|Journal of Clinical Oncology|2021|818
Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
|Journal of Clinical Oncology|2017|653
Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy
|Journal of Hematology & Oncology|2019|634